Open AccessGuidelines for Diagnosis and Treatment of Hepatocellular Carcinoma with Portal Vein Tumor Thrombus in China (2021 Edition)
Author(s) -
Sun Juxian,
Guo Rongping,
Bi Xinyu,
Wu Mengchao,
Tang Zhaoyou,
Lau Wan Yee,
Zheng Shusen,
Wang Xuehao,
Yu Jinming,
Chen Xiaoping,
Fan Jia,
Dong Jiahong,
Chen Yongjun,
Cui Yunfu,
Dai Chaoliu,
Fang Chihua,
Feng Shuang,
Ji Zhili,
Jia Weidong,
Jia Ningyang,
Li Gong,
Li Jing,
Li Qiu,
Li Jiangtao,
Liang Tingbo,
Liu Lianxin,
Lu Shichun,
Lv Yi,
Mao Yilei,
Meng Yan,
Meng Zhiqiang,
Shen Feng,
Shi Jie,
Sun Huichuan,
Tao Kaishan,
Teng Gaojun,
Wan Xuying,
Wen Tianfu,
Wu Liqun,
Xia Jinglin,
Ying Mingang,
Zhai Jian,
Zhang Leida,
Zhang Xuewen,
Zhang Zhiwei,
Zhao Haiping,
Zheng Donghai,
Zhi Xuting,
Zhou Jie,
Zhou Cuncai,
Zhou Jian,
Zeng Zhaochong,
Zhu Kangshun,
Chen Minshan,
Cai Jianqiang,
Cheng Shuqun
Publication year - 2022
Publication title -
liver cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.916
H-Index - 34
eISSN - 1664-5553
pISSN - 2235-1795
DOI - 10.1159/000523997
Subject(s) - guidelines
Portal vein tumor thrombus (PVTT) is very common and it plays a major role in the prognosis and clinical staging of hepatocellular carcinoma (HCC). We have published the first version of the guideline in 2016 and revised in 2018. Over the past several years, many new evidences for the treatment of PVTT become available, especially for the advent of new targeted drugs and immune checkpoint inhibitors which have further improved the prognosis of PVTT. So, the Chinese Association of Liver Cancer and Chinese Medical Doctor Association revised the 2018 version of the guideline to adapt to the development of PVTT treatment. Future treatment strategies for HCC with PVTT in China would depend on new evidences from more future clinical trials.